Drug Profile
Biosimilar protein therapeutic - EPIRUS Biopharmaceuticals
Alternative Names: BOW 020Latest Information Update: 01 Aug 2016
Price :
$50
*
At a glance
- Originator EPIRUS Biopharmaceuticals
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 22 May 2015 Discontinued - Phase-III for Undefined indication in USA (Parenteral) (EPIRUS pipeline, May 2015)
- 22 May 2015 Phase-III clinical trials in Undefined indication in USA (Parenteral) before May 2015